ATE288764T1 - DETECTION OF HUMAN CYTOMEGALOVIRUS GENES THAT DECREASE THE EXPRESSION OF MHC CLASS I HEAVY CHAINS - Google Patents

DETECTION OF HUMAN CYTOMEGALOVIRUS GENES THAT DECREASE THE EXPRESSION OF MHC CLASS I HEAVY CHAINS

Info

Publication number
ATE288764T1
ATE288764T1 AT97936334T AT97936334T ATE288764T1 AT E288764 T1 ATE288764 T1 AT E288764T1 AT 97936334 T AT97936334 T AT 97936334T AT 97936334 T AT97936334 T AT 97936334T AT E288764 T1 ATE288764 T1 AT E288764T1
Authority
AT
Austria
Prior art keywords
mhc class
class
heavy chains
human cytomegalovirus
expression
Prior art date
Application number
AT97936334T
Other languages
German (de)
Inventor
Klaus Frueh
Young Yang
Kwangseog Ahn
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Application granted granted Critical
Publication of ATE288764T1 publication Critical patent/ATE288764T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

The human cytomegalovirus (HCMV) genomic US region encodes a family of homologous genes essential for the inhibition of major histocompatiblity complex (MHC) class I mediated antigen presentation observed during viral infection. Here we show that US3 and US6 encode ER-resident glycoproteins that prevent intracellular transport of NMC class I molecules by different mechanisms. US3 retains stable MHC class I heterodimers in the ER which are loaded with peptides while retained in the ER. US6 prevents MHC class I assembly with beta 2 microglobulin which results in free heavy chains leaving the ER. These genes have the potential to prevent unwanted immunological reactivities triggered by MHC class I molecules.
AT97936334T 1996-07-31 1997-07-31 DETECTION OF HUMAN CYTOMEGALOVIRUS GENES THAT DECREASE THE EXPRESSION OF MHC CLASS I HEAVY CHAINS ATE288764T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2284796P 1996-07-31 1996-07-31
US4621397P 1997-05-12 1997-05-12
PCT/US1997/013509 WO1998004285A1 (en) 1996-07-31 1997-07-31 Identification of human cytomegalovirus genes involved in down-regulation of mhc class i heavy chain expression

Publications (1)

Publication Number Publication Date
ATE288764T1 true ATE288764T1 (en) 2005-02-15

Family

ID=26696435

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97936334T ATE288764T1 (en) 1996-07-31 1997-07-31 DETECTION OF HUMAN CYTOMEGALOVIRUS GENES THAT DECREASE THE EXPRESSION OF MHC CLASS I HEAVY CHAINS

Country Status (8)

Country Link
US (1) US6033671A (en)
EP (1) EP0966301B1 (en)
AT (1) ATE288764T1 (en)
AU (1) AU730351B2 (en)
DE (1) DE69732498T2 (en)
ES (1) ES2237800T3 (en)
PT (1) PT966301E (en)
WO (1) WO1998004285A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998047914A2 (en) * 1997-04-18 1998-10-29 Roche Diagnostics Gmbh Us6 gene from the human cytomegalovirus (hcmv)
WO2002062296A2 (en) 2001-02-02 2002-08-15 Chemocentryx, Inc. Methods and compositions useful for stimulating an immune response
EP2140879A1 (en) * 2001-05-09 2010-01-06 M'S Science Corporation Composition and method for treating cancer using herpes virus
WO2011119920A2 (en) * 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
DK2569436T3 (en) 2010-05-14 2018-03-05 Univ Oregon Health & Science RECOMBINANT HCMV AND RHCMV VECTORS AND APPLICATIONS THEREOF
US20120020885A1 (en) * 2010-07-26 2012-01-26 Searete Llc, A Limited Liability Corporation Of The State Of Delaware MHC-Less cells
HUE037408T2 (en) 2011-06-10 2018-08-28 Univ Oregon Health & Science Cmv glycoproteins and recombinant vectors
SI2964769T1 (en) 2013-03-05 2018-12-31 Oregon Health & Sccience University Cytomegalovirus vectors enabling control of t cell targeting
MA39818A (en) 2014-03-30 2017-02-08 Benevir Biopharm Inc Exogenous tap inhibitor "armed" oncolytic viruses and therapeutic uses thereof
CA3113595A1 (en) 2014-07-16 2016-01-21 Oregon Health & Science University Human cytomegalovirus comprising exogenous antigens
AU2016219317A1 (en) 2015-02-10 2017-08-31 Oregon Health & Science University Methods and compositions useful in generating non canonical CD8+ T cell responses
MA43285A (en) 2015-11-20 2018-09-26 Univ Oregon Health & Science CMV VECTORS INCLUDING MICRORNA RECOGNITION ELEMENTS
CN109843321A (en) 2016-06-22 2019-06-04 国际艾滋病疫苗行动组织公司 Recombined cytomegalovirus carrier as tuberculosis vaccine
AU2017346788A1 (en) 2016-10-18 2019-05-02 Oregon Health & Science University Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules
WO2019079155A1 (en) 2017-10-17 2019-04-25 International Aids Vaccine Initiative, Inc. Tuberculosis antigen cassettes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877004A (en) * 1991-07-05 1999-03-02 American Cyanamid Compound Human cytomegalovirus containing a β-glucuronidase marker gene
US5846806A (en) * 1994-07-29 1998-12-08 American Cyanamid Company Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression
WO1998047914A2 (en) * 1997-04-18 1998-10-29 Roche Diagnostics Gmbh Us6 gene from the human cytomegalovirus (hcmv)

Also Published As

Publication number Publication date
WO1998004285A1 (en) 1998-02-05
AU3903297A (en) 1998-02-20
US6033671A (en) 2000-03-07
EP0966301B1 (en) 2005-02-09
ES2237800T3 (en) 2005-08-01
PT966301E (en) 2005-06-30
EP0966301A1 (en) 1999-12-29
AU730351B2 (en) 2001-03-08
EP0966301A4 (en) 2001-09-05
DE69732498T2 (en) 2006-04-27
DE69732498D1 (en) 2005-03-17

Similar Documents

Publication Publication Date Title
ATE288764T1 (en) DETECTION OF HUMAN CYTOMEGALOVIRUS GENES THAT DECREASE THE EXPRESSION OF MHC CLASS I HEAVY CHAINS
Dunn et al. Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity
Dill et al. Immunological function of HLA-C antigens in HLA-Cw3 transgenic mice.
US6361770B1 (en) Method of enhancing expression of MHC class I molecules bearing endogenous peptides
Carayannopoulos et al. Recognition of infected cells by natural killer cells
Davies et al. A peptide from heat shock protein 60 is the dominant peptide bound to Qa-1 in the absence of the MHC class Ia leader sequence peptide Qdm
US20060153841A1 (en) B7-4 polypeptides and uses therefor
Schirmbeck et al. Peptide transporter‐independent, stress protein‐mediated endosomal processing of endogenous protein antigens for major histocompatibility complex class I presentation
FI942503A (en) Immunotherapeutic anticancer vector constructs
Shim et al. The distribution of haptoglobin subtypes in various populations, including subtype patterns in some nonhuman primates
WO2003102023A1 (en) Tumour-associated peptides that bond to mhc molecules
Ruibal et al. Peptide binding to HLA-E molecules in humans, nonhuman primates, and mice reveals unique binding peptides but remarkably conserved anchor residues
Serna et al. Cutting edge: efficient MHC class I cross-presentation during early vaccinia infection requires the transfer of proteasomal intermediates between antigen donor and presenting cells
Forte et al. HLA‐E expression on porcine cells: protection from human NK cytotoxicity depends on peptide loading
Pandiyan et al. High IFN-γ production of individual CD8 T lymphocytes is controlled by CD152 (CTLA-4)
Miller et al. CD94/NKG2 expression does not inhibit cytotoxic function of lymphocytic choriomeningitis virus-specific CD8+ T cells
Pettigrew et al. Indirect T cell allorecognition and alloantibody-mediated rejection of MHC class I-disparate heart grafts
Speiser et al. Nuclear myxovirus-resistance protein Mx is a minor histocompatibility antigen.
Tomescu et al. Identification of the predominant human NK cell effector subset mediating ADCC against HIV‐infected targets coated with BNAbs or plasma from PLWH
Yamada et al. Proline 78 is crucial for human immunodeficiency virus type 1 Nef to down-regulate class I human leukocyte antigen
HUP9802587A2 (en) Glucose-inducible recombinant viral vector, pharmaceutical composition containing it and cells transformed by this
Sarmiento et al. Cell surface polypeptides of murine T-cell clones expressing cytolytic or amplifier activity.
Thorsby MHC structure and function
US20180325979A1 (en) Peptide-induced nk cell activation
US10995116B2 (en) Peptide-induced NK cell activation

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0966301

Country of ref document: EP